Elutia Inc. (ELUT) is a Biotechnology company in the Healthcare sector, currently trading at $1.17. It has a SharesGrow Score of 71/100, indicating a above average investment profile with 3 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of ELUT = $28.86 (+2366.7% from the current price, the stock appears undervalued). Analyst consensus target is ELUT = $9 (+659% upside).
Valuation: ELUT trades at a trailing Price-to-Earnings (P/E) of 0.9 (S&P 500 average ~25).
Financials: revenue is $12M, -15.8%/yr average growth. Net income is $53M, growing at +47.1%/yr. Net profit margin is 434.2% (strong). Gross margin is 53.7% (+4.9 pp trend).
Balance sheet: total debt is $8M against $28M equity (Debt-to-Equity (D/E) ratio 0.27, conservative). Current ratio is 2.22 (strong liquidity). Debt-to-assets is 12.2%. Total assets: $62M.
Analyst outlook: 5 / 5 analysts rate ELUT as buy (100%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 25/100 (Fail), Health 67/100 (Partial), Moat 50/100 (Partial), Future 100/100 (Pass), Income 100/100 (Pass).
